Interleukin-17A (IL-17A) is produced by Th17 cells which infiltrate the tumor microenvironment and induces the expression of several inflammatory cytokines including IL-1β, IL-16 and IL-23, leading to variable effects on tumor growth at different stages [19,20]. This evidence concerns the gene IL16 and neoplasm.